Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Vascular disrupting agents.

Lippert JW 3rd.

Bioorg Med Chem. 2007 Jan 15;15(2):605-15. Epub 2006 Oct 27.

PMID:
17070061
2.

Small molecule vascular disrupting agents: potential new drugs for cancer treatment.

Cai SX.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. Review.

PMID:
18221055
3.

The first international conference on vascular targeting: meeting overview.

Thorpe PE, Chaplin DJ, Blakey DC.

Cancer Res. 2003 Mar 1;63(5):1144-7.

4.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
5.

Vascular disrupting agents: a new class of drug in cancer therapy.

Gaya AM, Rustin GJ.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):277-90. Review.

PMID:
15997924
6.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
7.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

8.

Vascular disrupting agents.

Pilat MJ, Lorusso PM.

J Cell Biochem. 2006 Nov 1;99(4):1021-39.

PMID:
16927308
9.

Disrupting tumour blood vessels.

Tozer GM, Kanthou C, Baguley BC.

Nat Rev Cancer. 2005 Jun;5(6):423-35. Review.

PMID:
15928673
10.

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.

Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, Colantuoni G.

Oncologist. 2009 Jun;14(6):612-20. doi: 10.1634/theoncologist.2008-0287. Epub 2009 May 27. Review.

11.

Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.

Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC.

Nat Clin Pract Oncol. 2006 Dec;3(12):682-92. Review.

PMID:
17139319
12.

Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.

Iversen AB, Busk M, Horsman MR.

Acta Oncol. 2013 Oct;52(7):1320-6. doi: 10.3109/0284186X.2013.825050. Epub 2013 Aug 29.

PMID:
23988183
13.

Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.

Van Langendonckt A, Donnez J, Defrère S, Dunselman GA, Groothuis PG.

Mol Hum Reprod. 2008 May;14(5):259-68. doi: 10.1093/molehr/gan019. Epub 2008 Apr 22. Review.

14.

Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

Spear MA, LoRusso P, Mita A, Mita M.

Curr Drug Targets. 2011 Dec;12(14):2009-15. Review.

PMID:
21777190
15.

Vascular targeting agents.

Pilat MJ, McCormick J, LoRusso PM.

Curr Oncol Rep. 2004 Mar;6(2):103-10. Review.

PMID:
14751087
16.

Vascular disrupting agents in clinical development.

Hinnen P, Eskens FA.

Br J Cancer. 2007 Apr 23;96(8):1159-65. Epub 2007 Mar 20. Review.

17.

Vascular damaging agents.

Patterson DM, Rustin GJ.

Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56. Epub 2007 Apr 24. Review.

PMID:
17459681
18.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

19.

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Cooney MM, Ortiz J, Bukowski RM, Remick SC.

Curr Oncol Rep. 2005 Mar;7(2):90-5. Review.

PMID:
15717941
20.

Angiogenesis and vascular targeting: relevance for hyperthermia.

Horsman MR.

Int J Hyperthermia. 2008 Feb;24(1):57-65. doi: 10.1080/02656730701829710. Review.

PMID:
18214769
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk